Your browser doesn't support javascript.
loading
Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study.
Hilton, Laura K; Collinge, Brett J; Ben-Neriah, Susana; Alduaij, Waleed; Shaalan, Haya; Weng, Andrew; Cruz, Manuela; Slack, Graham W; Farinha, Pedro; Miyata-Takata, Tomoko; Boyle, Merrill; Meissner, Barbara; Cook, James R; Ondrejka, Sarah L; Ott, German; Rosenwald, Andreas; Campo, Elías; Amador, Catalina; Greiner, Timothy C; Raess, Philipp W; Song, Joo Y; Inghirami, Giorgio Ga; Jaffe, Elaine S; Weisenburger, Dennis D; Chan, Wing C; Beiske, Klaus; Fu, Kai; Delabie, Jan; Pittaluga, Stafania; Iqbal, Javeed; Wright, George; Sehn, Laurie H; Savage, Kerry J; Mungall, Andrew J; Feldman, Andrew L; Staudt, Louis M; Steidl, Christian; Rimsza, Lisa M; Morin, Ryan D; Scott, David W.
Afiliación
  • Hilton LK; BC Cancer, Vancouver, British Columbia, Canada.
  • Collinge BJ; BC Cancer, Vancouver, British Columbia, Canada.
  • Ben-Neriah S; BC Cancer, Vancouver, British Columbia, Canada.
  • Alduaij W; University of British Columbia, Vancouver, British Columbia, Canada.
  • Shaalan H; Simon Fraser University, Burnaby, British Columbia, Canada.
  • Weng A; BC Cancer Agency, Vancouver, British Columbia, Canada.
  • Cruz M; Simon Fraser University, Burnaby, British Columbia, Canada.
  • Slack GW; British Columbia Cancer Agency, Vancouver, Canada.
  • Farinha P; British Columbia Cancer, Vancouver, Canada.
  • Miyata-Takata T; BC Cancer, Vancouver, British Columbia, Canada.
  • Boyle M; BC Cancer, Vancouver, British Columbia, Canada.
  • Meissner B; BC Cancer Agency, Vancouver, Canada.
  • Cook JR; Cleveland Clinic, Cleveland, Ohio, United States.
  • Ondrejka SL; Cleveland Clinic, Cleveland, Ohio, United States.
  • Ott G; Robert-Bosch-Krankenhaus, Stuttgart, Germany.
  • Rosenwald A; Universität Würzburg.
  • Campo E; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Amador C; University of Miami, Miami, Florida, United States.
  • Greiner TC; University of Nebraska Medical Center, Omaha, Nebraska, United States.
  • Raess PW; Oregon Health & Science University, Portland, Oregon, United States.
  • Song JY; City of Hope Medical Center, Duarte, California, United States.
  • Inghirami GG; Weill Cornell Medicine, New York, New York, United States.
  • Jaffe ES; National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States.
  • Weisenburger DD; University of Nebraska Medical Center, Omaha, Nebraska, United States.
  • Chan WC; City of Hope National Medical Center, Duarte, California, United States.
  • Beiske K; Oslo University Hospital Radiumhospitalet, Oslo, Norway.
  • Fu K; 9. Department of Pathology, Roswell Park Comprehensive Cancer Center, New York, New York, United States.
  • Delabie J; University of Toronto and University Health Network, Toronto, Toronto, Ontario, Canada.
  • Pittaluga S; National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States.
  • Iqbal J; University of Nebraska Medical Center, Omaha, Nebraska, United States.
  • Wright G; NIH/NCI, Rockville, Maryland, United States.
  • Sehn LH; BC Cancer, Vancouver, Canada.
  • Savage KJ; BC Cancer, Centre for Lymphoid Cancer, Vancouver, Canada.
  • Mungall AJ; BC Cancer, Vancouver, British Columbia, Canada.
  • Feldman AL; Mayo Clinic, Rochester, Minnesota, United States.
  • Staudt LM; National Cancer Institute, Bethesda, Maryland, United States.
  • Steidl C; BC Cancer, Vancouver, British Columbia, Canada.
  • Rimsza LM; Mayo Clinic, Scottsdale, Arizona, United States.
  • Morin RD; BC Cancer, Canada.
  • Scott DW; BC Cancer, Vancouver, Canada.
Blood ; 2024 May 03.
Article en En | MEDLINE | ID: mdl-38701426
ABSTRACT
Rearrangements that place the oncogenes MYC, BCL2, or BCL6 adjacent to superenhancers are common in mature B-cell lymphomas. Lymphomas with diffuse large B-cell lymphoma (DLBCL) or high-grade morphology with both MYC and BCL2 rearrangements are classified as high-grade B-cell lymphoma with MYC and BCL2 rearrangements ("double hit" HGBCL-DH-BCL2) and are associated with aggressive disease and poor outcomes. Although it is established that MYC rearrangements involving immunoglobulin (IG) loci are associated with inferior outcomes relative to those involving other non-IG superenhancers, the frequency of, and mechanisms driving, IG vs non-IG MYC rearrangements have not been elucidated. Here we used custom targeted capture and/or whole genome sequencing to characterize oncogene rearrangements across 883 mature B-cell lymphomas including Burkitt lymphoma, follicular lymphoma, DLBCL, and HGBCL-DH-BCL2 tumors. We demonstrate that, while BCL2 rearrangement topology is consistent across entities, HGBCL-DH-BCL2 have distinct MYC rearrangement architecture relative to tumors with single MYC rearrangements or with both MYC and BCL6 rearrangements (HGBCL-DH-BCL6), including both a higher frequency of non-IG rearrangements and different architecture of MYCIGH rearrangements. The distinct MYC rearrangement patterns in HGBCL-DH-BCL2 occur on the background of high levels of somatic hypermutation across MYC partner loci in HGBCL-DH-BCL2, creating more opportunity to form these rearrangements. Furthermore, because one IGH allele is already disrupted by the existing BCL2 rearrangement, the MYC rearrangement architecture in HGBCL-DH-BCL2 likely reflects selective pressure to preserve both BCL2 and B cell receptor expression. These data provide new mechanistic explanations for the distinct patterns of MYC rearrangements observed across different lymphoma entities.

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Blood Año: 2024 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Blood Año: 2024 Tipo del documento: Article País de afiliación: Canadá